Search

Memorial Sloan Kettering Cancer Center and MediSys Health Network today announced a new collaboration that will expand access to world-class cancer care for the people of Queens and eastern Brooklyn.

… Thursday, January 12, 2023 Memorial Sloan Kettering Cancer Center (MSK) and MediSys Health Network (Jamaica Hospital Medical Center and Flushing Hospital Medical Center) today announced a new collaboration that will expand access to world-class cancer care for the people of Queens and eastern Brooklyn

By sequencing the entire genome of a tumor, the experimental test will go beyond standard testing for common cancers in adults.

… Wednesday, May 18, 2022 New findings from researchers at Memorial Sloan Kettering Cancer Center (MSK) and published today in the journal Nature Communications report the results of using a comprehensive sequencing approach on 114 pediatric, adolescent, and young adult patients with solid tumors. The

Naxitamab was created at MSK and has received Breakthrough Therapy Designation from the FDA.

… Friday, September 28, 2018 Summary Naxitamab was created at MSK and has received Breakthrough Therapy Designation from the FDA for the treatment of patients with high-risk neuroblastoma. Neuroblastoma is a rare cancer of the nerve tissue that usually arises in the abdomen. It mainly affects young children

A vital part of MSK's mission is to get patients back to feeling like themselves.

… Wednesday, July 12, 2017 VIDEO | 01:35 MSK's Dental Service Aims to Make People Whole Again Medical artist Marjorie Golden and Dental Service Chief Joseph Huryn create lifelike facial prostheses for patients. Video Details Summary A vital part of MSK’s mission is to get patients back to feeling like

MSK’s comprehensive program for patients with upper tract urothelial carcinoma (UTUC) offers kidney-sparing treatment options whenever possible.

… Tuesday, April 16, 2024 MSK’s comprehensive program for patients with upper tract urothelial carcinoma (UTUC) offers kidney-sparing treatment options whenever possible. “Traditionally, radical nephroueterectomy has been the gold standard for managing high-risk UTUC,” said  urologic surgeon Jonathan Coleman

Charles L. Sawyers, Chair of the Human Oncology and Pathogenesis Program, is a co-recipient of the 2011 Stanley J. Korsmeyer Award from the American Society for Clinical Investigation.

… Friday, July 1, 2011 Summary Charles L. Sawyers, Chair of the Human Oncology and Pathogenesis Program, is a co-recipient of the 2011 Stanley J. Korsmeyer Award from the American Society for Clinical Investigation. Charles L. Sawyers , Chair of the Human Oncology and Pathogenesis Program , is a co-recipient

First-year students reflect on the impact of the first-year core curriculum on their careers.

… Thursday, April 1, 2010 Our current first-year students arrived on July 27, 2009, and during their first laboratory rotation began laying the foundation for developing a dissertation. After five weeks of bench work, they entered the classroom to tackle the core course, taking breaks from this didactic

Charles Swanton of Cancer Research UK and University College London was one of the recipients of the 2021 Paul Marks Prize for Cancer Research.

… Thursday, March 17, 2022 The Paul Marks Prize for Cancer Research was created by the Boards of Memorial Sloan Kettering Cancer Center to honor the late Paul Marks , who served as President and CEO of MSK for almost 20 years, beginning in 1980. Awarded every other year since 2001, the prize recognizes

Computational biology is helping to bring predictive power and precision to oncology.

… Wednesday, April 1, 2020 By Julie Grisham It was July 17, 2017, when Albert Kuchler found an unusual lump in his neck. As a retired oral surgeon, he knew this was cause for concern. He called his friend and colleague Jatin Shah , a member of Memorial Sloan Kettering’s Head and Neck Service, to see if

Research led by investigators at Memorial Sloan Kettering has shown for the first time that organoids derived from human prostate cancer tumors can be grown in the laboratory.

… Thursday, September 4, 2014 Research led by investigators at Memorial Sloan Kettering Cancer Center has shown for the first time that organoids derived from human prostate cancer tumors can be grown in the laboratory, giving researchers an exciting new tool to test cancer drugs and personalize cancer